GU CONNECT Prostate Cancer Update from ASCO GU 2020 (1 of 3)
GU CONNECT Prostate Cancer Update from ASCO GU 2020 (1 of 3)
Dr Neal D. Shore
GU CONNECT expert, Dr. Neal Shore provides a prostate cancer update from ASCO GU 2020 for you.Dr Neal D. Shore
Urologist
Carolina Urologic Research Centre and GenesisCare
United States (US)
Neal D. Shore, MD, FACS is the Medical Director for the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina. Dr. Shore has conducted more than 350 clinical trials, focusing mainly on GU Oncology, and serves on the Executive Boards of: Society of Urologic Oncology Board, Bladder Cancer Advocacy Network, and is Immediate Past President, Large Urology Group Practice Association. He is a founder for both: CUSP Clinical Trials Consortium, as well as for DASHKO, large urology practices data registries. He serves as the National Urology Research Director for 21st Century Oncology. He has served on the AUA Male Health Committee and the AUA Data Committee, the SITC Task Force for Prostate Cancer, the Bladder Cancer Advocacy Think Tank and the editorial boards of Reviews in Urology, Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE(Academic Editor), Urology Practice, World Journal of Urology, and serves as Editor, Everyday Urology-Oncology. He has more than 200 peer reviewed publications and numerous book chapters; he performs peer review for Lancet Oncology, New England Journal of Medicine, European Urology, Journal Urology, Urology, BJUI, PCPD, and numerous other high impact scientific journals. A graduate of Duke University and Duke University Medical School, Dr. Shore completed a 6-month clinical research fellowship in Pretoria, South Africa, and then completed his General Surgery/Urology training at New York Hospital Cornell Medical Center and at Memorial Sloan-Kettering Cancer Center in New York City. He is a Fellow of the American College of Surgeons.
Dr Neal D. Shore has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Abbvie, Amgen, Astellas, AstraZeneca, Bayer, BMS, Boston Scientific, Clovis Oncology, Cold Genesys, Dendreon Exact Imaging, Exact Sciences, FerGene Foundation Medicine, Genesis Care, Invitae, Janssen, MDxHealth, Merck, Myovant, Myriad, Nymox, Pacific Edge, Pfizer, Phosphorous, Propella, PreView, Sanofi Genzyme, Speciality Networks, Sensen Bio, Tolmar and Urogen.
|
5 min
|
Feb 2020
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
download resources
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
Prostate cancer update by Dr. Neal Shore, Carolina Urologic Research Center, South Carolina, USA.
GU CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from AstraZeneca, Bayer and Eisai Europe Limited.